Research Topics
Species | Christopher C RoweSummaryAffiliation: Austin Health Country: Australia Publications
| Collaborators
|
Detail Information
Publications
Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's diseaseKerryn E Pike
School of Psychology, Psychiatry and Psychological Medicine, Monash University, Melbourne, Australia
Brain 130:2837-44. 2007..The data also suggests that early intervention trials for AD targeted to non-demented individuals with cerebral Abeta deposition are warranted...
The ART of loss: Abeta imaging in the evaluation of Alzheimer's disease and other dementiasVictor L Villemagne
Department of Nuclear Medicine, Centre for PET, Austin Health, 145 Studley Road, Heidelberg, Victoria 3084, Australia
Mol Neurobiol 38:1-15. 2008..Further longitudinal observations are required to confirm this hypothesis and to better elucidate the role of Abeta deposition in the course of Alzheimer's disease...- Imaging beta-amyloid burden in aging and dementiaC C Rowe
Department of Nuclear Medicine, Centre for PET, Austin Health, Heidelberg, Victoria, Australia
Neurology 68:1718-25. 2007..To compare brain beta-amyloid (Abeta) burden measured with [(11)C]Pittsburgh Compound B (PIB) PET in normal aging, Alzheimer disease (AD), and other dementias... - Imaging of amyloid beta in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanismChristopher C Rowe
Department of Nuclear Medicine and Centre for PET, Austin Health, Heidelberg, Victoria, Australia
Lancet Neurol 7:129-35. 2008..18)F-BAY94-9172 is an Abeta ligand that, due to the half-life of (18)F, is suitable for clinical use. We thus studied the effectiveness of this ligand in identifying patients with AD... - Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of agingChristopher C Rowe
Austin Health, Department of Nuclear Medicine and Centre for PET, Heidelberg, Victoria, Australia
Neurobiol Aging 31:1275-83. 2010.... - Brain amyloid imagingChristopher C Rowe
Department of Nuclear Medicine and Centre for PET, Austin Health, Melbourne, Australia
J Nucl Med Technol 41:11-8. 2013..This article will provide nuclear medicine physicians with the background knowledge required for understanding this emerging investigation, including its appropriate use, and prepare them for practical training in scan interpretation... - Brain amyloid imagingChristopher C Rowe
Department of Nuclear Medicine and Centre for PET, Austin Health, Melbourne, Australia
J Nucl Med 52:1733-40. 2011..This article will provide nuclear medicine physicians with the background knowledge required for understanding this emerging investigation, including its appropriate use, and prepare them for practical training in scan interpretation... - Relationship between atrophy and beta-amyloid deposition in Alzheimer diseaseGael Chetelat
Department of Nuclear Medicine and Center for PET, Austin Health, 145 Studley Road, Heidelberg, Victoria 3084, Australia
Ann Neurol 67:317-24. 2010..The present study aims to assess this relationship... - Differential diagnosis in Alzheimer's disease and dementia with Lewy bodies via VMAT2 and amyloid imagingVictor L Villemagne
Mental Health Research Institute, University of Melbourne, Melbourne, Vic, Australia
Neurodegener Dis 10:161-5. 2012..The noninvasive evaluation of nigrostriatal dopaminergic integrity by PET can provide useful information for the differential diagnosis between dementia with Lewy bodies (DLB) and Alzheimer's disease (AD)... 
Longitudinal assessment of Aβ and cognition in aging and Alzheimer diseaseVictor L Villemagne
Department of Nuclear Medicine and Centre for PET, Austin Health, Heidelberg, Australia
Ann Neurol 69:181-92. 2011..Assess Aβ deposition longitudinally and explore its relationship with cognition and disease progression...- In vivo assessment of vesicular monoamine transporter type 2 in dementia with lewy bodies and Alzheimer diseaseVictor L Villemagne
Department of Nuclear Medicine, Centre for Positron Emission Tomography, Austin Hospital, Austin Health, Heidelber, Australia
Arch Neurol 68:905-12. 2011..Design, Setting, and.. - Amyloid imaging with (18)F-florbetaben in Alzheimer disease and other dementiasVictor L Villemagne
Department of Nuclear Medicine and Centre for PET, Austin Health, Heidelberg, Victoria, Australia
J Nucl Med 52:1210-7. 2011.... - Cognition and beta-amyloid in preclinical Alzheimer's disease: data from the AIBL studyKerryn E Pike
Department of Nuclear Medicine, Centre for PET, Austin Health, Heidelberg, Vic, Australia
Neuropsychologia 49:2384-90. 2011..The finding of gender differences deserves further research to answer definitively the important question of gender susceptibility to adverse cognitive effects from β-amyloid... - Independent contribution of temporal beta-amyloid deposition to memory decline in the pre-dementia phase of Alzheimer's diseaseGael Chetelat
Department of Nuclear Medicine and Centre for PET, Austin Health, 145 Studley Road, Heidelberg, VIC 3084, Australia
Brain 134:798-807. 2011.... - Increasing the predictive accuracy of amyloid-β blood-borne biomarkers in Alzheimer's diseaseAndrew D Watt
Department of Pathology, The University of Melbourne, Parkville, Melbourne, Victoria, Australia
J Alzheimers Dis 24:47-59. 2011..Furthermore, the findings indicate that the incorporation of non-amyloid markers into predictive models, function to increase the accuracy of the diagnostic potential of Aβ... - Comparison of 11C-PiB and 18F-florbetaben for Aβ imaging in ageing and Alzheimer's diseaseVictor L Villemagne
Department of Nuclear Medicine and Centre for PET, Austin Health, 145 Studley Road, Heidelberg, VIC 3084, Australia
Eur J Nucl Med Mol Imaging 39:983-9. 2012..The purpose of this analysis was to compare data on cortical Aβ deposition in subjects who had undergone both (11)C-PiB (PiB) and (18)F-florbetaben (FBB) PET imaging... - Addressing population aging and Alzheimer's disease through the Australian imaging biomarkers and lifestyle study: collaboration with the Alzheimer's Disease Neuroimaging InitiativeKathryn A Ellis
Department of Psychiatry, Academic Unit for Psychiatry of Old Age, University of Melbourne, Kew, Victoria, Australia
Alzheimers Dement 6:291-6. 2010..Cross-sectional analysis of baseline data is revealing links between cognition, brain amyloid burden, structural brain changes, biomarkers, and lifestyle... - Characterization of PiB binding to white matter in Alzheimer disease and other dementiasMichelle T Fodero-Tavoletti
Department of Pathology, University of Melbourne, and Department of Nuclear Medicine, Centre for PET, Austin Hospital, Heidelberg, Victoria, Australia
J Nucl Med 50:198-204. 2009..Although the specificity of PiB for Abeta plaques in gray matter has been well described, the nature of PiB binding to white matter remains unclear. In this study, we characterized the binding of PiB to human white matter homogenates... - Relationship between memory performance and β-amyloid deposition at different stages of Alzheimer's diseaseGael Chetelat
Department of Nuclear Medicine and Centre for PET, Austin Health, Heidelberg, Vic, Australia
Neurodegener Dis 10:141-4. 2012..The development of Aβ ligands for in vivo PET imaging has greatly facilitated the assessment of this question... - In vivo measurement of vesicular monoamine transporter type 2 density in Parkinson disease with (18)F-AV-133Nobuyuki Okamura
Department of Nuclear Medicine and Centre for PET, Austin Health, Victoria, Australia
J Nucl Med 51:223-8. 2010..PET provides a noninvasive means to evaluate the functional integrity of the presynaptic monoaminergic system in the living human brain... - Advances in structural and molecular neuroimaging in Alzheimer's diseaseKathryn A Ellis
Academic Unit for Psychiatry of Old Age, Department of Psychiatry, University of Melbourne, Melbourne, Vic, Australia
Med J Aust 194:S20-3. 2011.... - The 18F-FDG PET cingulate island sign and comparison to 123I-beta-CIT SPECT for diagnosis of dementia with Lewy bodiesSeok Ming Lim
Department of Nuclear Medicine and Centre for PET, Austin Health, Victoria, Australia
J Nucl Med 50:1638-45. 2009.... - Radiation dosimetry of beta-amyloid tracers 11C-PiB and 18F-BAY94-9172Graeme J O'Keefe
Centre for Positron Emission Tomography, Austin Hospital, Heidelberg, Victoria, Australia
J Nucl Med 50:309-15. 2009..The radiation dosimetry of Abeta radioligands may influence their application; therefore, we calculated and compared the effective doses (EDs) of 11C-PiB and a new 18F-labeled ligand, 18F-BAY94-9172... - Evaluating atypical dementia syndromes using positron emission tomography with carbon 11 labeled Pittsburgh Compound BSteven Y Ng
Department of Nuclear Medicine and Centre for Positron Emission Tomography, Austin Health, Melbourne, Australia
Arch Neurol 64:1140-4. 2007..However, patients presenting with atypical or focal clinical symptoms such as language or visuospatial dysfunction often pose a diagnostic challenge... - Larger temporal volume in elderly with high versus low beta-amyloid depositionGael Chetelat
Department of Nuclear Medicine and Centre for PET, Austin Health, 145 Studley Road, Heidelberg, VIC 3084, Australia
Brain 133:3349-58. 2010..Our complementary analyses tend to support the latter hypotheses. Overall, our findings suggest that the deleterious effects of β-amyloid on cognition may be delayed in those subjects with larger brain (temporal) volume... - High striatal amyloid beta-peptide deposition across different autosomal Alzheimer disease mutation typesVictor L Villemagne
Department of Nuclear Medicine, Centre for Positron Emission Tomography, Austin Health, Heidelberg, Australia
Arch Neurol 66:1537-44. 2009..Mutations in the amyloid precursor protein (APP), presenilin 1 (PSEN1), and presenilin 2 (PSEN2) genes lead to increased Abeta levels before symptoms arise... - 18F-THK523: a novel in vivo tau imaging ligand for Alzheimer's diseaseMichelle T Fodero-Tavoletti
Department of Pathology, The University of Melbourne, Victoria, 3010, Australia
Brain 134:1089-100. 2011..The preclinical examination of THK523 has demonstrated its high affinity and selectivity for tau pathology both in vitro and in vivo, indicating that (18)F-THK523 fulfils ligand criteria for human imaging trials... - Amyloid imaging in Alzheimer's disease and other dementiasMichelle T Fodero-Tavoletti
Department of Pathology, The University of Melbourne, Melbourne, Victoria, 3010, Australia
Brain Imaging Behav 3:246-61. 2009.... - Quantitative approaches to amyloid imagingVictor L Villemagne
Department of Nuclear Medicine, Centre for PET, Austin Health, Heidelberg, VIC 3084, Australia
Methods Mol Biol 680:201-25. 2011..With the availability of novel amyloid imaging agents radiolabeled with either (11)C (half-life 20 min) or (18)F (half-life 110 min), a description of different image acquisition approaches is provided... - Assessment of the role of FDG PET in the diagnosis and management of children with refractory epilepsyGlenn P Ollenberger
Department of Nuclear Medicine and Centre for PET, University of Melbourne, Melbourne, Australia
Eur J Nucl Med Mol Imaging 32:1311-6. 2005..In the future, analysis of FDG PET data in specific subpopulations of children with refractory epilepsy may lead to novel insights regarding aetiology... - Blood-borne amyloid-beta dimer correlates with clinical markers of Alzheimer's diseaseVictor L Villemagne
Mental Health Research Institute, The University of Melbourne, Parkville, Melbourne, Victoria 3052, Australia
J Neurosci 30:6315-22. 2010..These results indicate that fundamental biochemical events relevant to AD can be monitored in blood, and that the species detected may be useful clinical biomarkers for AD... - Visual assessment versus quantitative assessment of 11C-PIB PET and 18F-FDG PET for detection of Alzheimer's diseaseSteven Ng
Department of Nuclear Medicine, Centre for PET, Austin Health, Heidelberg, Victoria, Australia
J Nucl Med 48:547-52. 2007..The aim of this study was to explore the clinical potential of Abeta imaging for the diagnosis of AD by comparison of the accuracy of visual reading of (11)C-PIB images with quantitative analysis and (18)F-FDG... - Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort studyVictor L Villemagne
Department of Nuclear Medicine and Centre for PET, Austin Health, Melbourne, VIC 3084, Australia
Lancet Neurol 12:357-67. 2013..We aimed to use longitudinal data to calculate the rates of amyloid β (Aβ) deposition, cerebral atrophy, and cognitive decline... - Amyloid imagingVictor L Villemagne
Department of Nuclear Medicine and Centre for PET, Austin Health, Victoria, Australia
Int Psychogeriatr 23:S41-9. 2011..Further longitudinal observations, coupled with different disease-specific tracers and biomarkers, are required to confirm this hypothesis and further elucidate the precise role of Aβ deposition in the course of AD... - Cerebral β-amyloid detected by Pittsburgh compound B positron emission topography predisposes to recombinant tissue plasminogen activator-related hemorrhageJohn V Ly
National Stroke Research Institute, Austin Health, University of Melbourne, Heidelberg Heights, Australia
Ann Neurol 68:959-62. 2010..This finding may provide an impetus for the development of a more practical rapid pretreatment screening technique... - 11C-PiB PET ABri imaging in Worster-Drought syndrome (familial British dementia): a case reportVictor L Villemagne
Mental Health Research Institute, University of Melbourne, Melbourne, Vic, Australia
J Alzheimers Dis 19:423-8. 2010..We speculate that the sparsity of ABri plaques in the neocortex together with its high deposition in the cerebellum, might explain the observed pattern of 11C-PiB retention... - Simplified quantification of nicotinic receptors with 2[18F]F-A-85380 PETSascha Mitkovski
Department of Nuclear Medicine and Centre for PET, Austin Hospital, Victoria 3084, Melbourne, Australia
Nucl Med Biol 32:585-91. 2005.... - Protocol for a randomized controlled trial evaluating the effect of physical activity on delaying the progression of white matter changes on MRI in older adults with memory complaints and mild cognitive impairment: the AIBL Active trialElizabeth V Cyarto
National Ageing Research Institute, Melbourne, Australia
BMC Psychiatry 12:167. 2012..The aim of AIBL Active is to determine whether a 24-month physical activity program can delay the progression of white matter changes on magnetic resonance imaging (MRI)... - In vitro characterization of Pittsburgh compound-B binding to Lewy bodiesMichelle T Fodero Tavoletti
Department of Pathology, The University of Melbourne, Melbourne, Victoria 3010, Australia
J Neurosci 27:10365-71. 2007..These studies indicate that PIB retention observed within the cortical gray matter regions of DLB subjects in [11C]-PIB PET studies is largely attributable to PIB binding to Abeta plaques and not Lewy bodies... - Prediction of amyloid-β pathology in amnestic mild cognitive impairment with neuropsychological testsAlex Bahar-Fuchs
Department of Nuclear Medicine, Centre for PET, Austin Health, Melbourne, Vic, Australia
J Alzheimers Dis 33:451-62. 2013..In conclusion, a measure of story recall may increase the confidence in making a diagnosis of MCI due to AD in clinical settings... - Quantitative gait analysis in patients with dementia with Lewy bodies and Alzheimer's diseaseJohn R Merory
Medical and Cognitive Research Unit, Neurology Department, Austin Health, Melbourne, Australia
Gait Posture 26:414-9. 2007..Significant correlations were found between gait speeds and gait outcome variables. Spatiotemporal gait characteristics of people with AD and DLB are similar, but significantly different from the normal population... - Abeta deposits in older non-demented individuals with cognitive decline are indicative of preclinical Alzheimer's diseaseV L Villemagne
Department of Nuclear Medicine, Centre for PET, Austin Health, 145 Studley Road, Heidelberg, VIC 3084, Australia
Neuropsychologia 46:1688-97. 2008..These observations suggest that neither memory decline nor Abeta deposition are part of normal ageing and likely represent preclinical AD. Further longitudinal observations are required to confirm this hypothesis... - Imaginem oblivionis: the prospects of neuroimaging for early detection of Alzheimer's diseaseVictor L Villemagne
Department of Nuclear Medicine, Centre for PET, Austin Hospital, Melbourne, Vic, Australia
J Clin Neurosci 12:221-30. 2005..From this, the prospect of specific preclinical diagnosis arises, possibly in conjunction with other related A beta biomarkers in plasma and CSF... - Long night's journey into the day: amyloid-β imaging in Alzheimer's diseaseVictor L Villemagne
Department of Nuclear Medicine and Centre for PET, Austin Health, Heidelberg, Vic, Australia
J Alzheimers Dis 33:S349-59. 2013.... - Positron emission tomography with selected mediastinoscopy compared to routine mediastinoscopy offers cost and clinical outcome benefits for pre-operative staging of non-small cell lung cancerKelvin K Yap
Centre for PET, University of Melbourne, Austin Hospital Heidelberg, Victoria, 3084, Australia
Eur J Nucl Med Mol Imaging 32:1033-40. 2005..These cost savings remain robust over a wide range of disease prevalence and FDG-PET costs... - Relationship between nicotinic receptors and cognitive function in early Alzheimer's disease: a 2-[18F]fluoro-A-85380 PET studyJ R Ellis
Department of Nuclear Medicine and Centre for PET, Austin Hospital, 145 Studley Road, Heidelberg, Victoria 3084, Australia
Neurobiol Learn Mem 90:404-12. 2008..It is possible that while the clinical 2-FA PET method described here may be insensitive in detecting changes in early AD, such changes may be detected in more advanced stages of the illness... - 11C-PiB PET studies in typical sporadic Creutzfeldt-Jakob diseaseV L Villemagne
Department of Nuclear Medicine, Centre for PET, Austin Health, 145 Studley Road, Heidelberg, VIC 3084, Australia
J Neurol Neurosurg Psychiatry 80:998-1001. 2009..The purpose of this study was to explore the premortem diagnostic utility of (11)C-PiB PET in sporadic Creutzfeldt-Jakob disease (CJD)... - Galantamine-induced improvements in cognitive function are not related to alterations in alpha(4)beta (2) nicotinic receptors in early Alzheimer's disease as measured in vivo by 2-[18F]fluoro-A-85380 PETJ R Ellis
School of Psychology, Psychiatry, and Psychological Medicine, Monash University, Melbourne, Victoria, Australia
Psychopharmacology (Berl) 202:79-91. 2009..e., galantamine) that potentiate cholinergic neurotransmission improve cognitive function in Alzheimer's disease (AD); however, the relationship between these effects and associated changes in nAChRs are yet to be established in vivo... - The relationship between nicotinic receptors and cognitive functioning in healthy aging: An in vivo positron emission tomography (PET) study with 2-[(18)F]fluoro-A-85380J R Ellis
Monash University, Victoria, Australia
Synapse 63:752-63. 2009..However, this approach may be appropriate for use in pathologies considered to undergo extensive nAChR loss such as Alzheimer's disease and Parkinson's disease... - Rare genetically defined causes of dementiaK E Novakovic
Department of Nuclear Medicine, Centre for PET Austin Hospital, Melbourne, Victoria, Australia
Int Psychogeriatr 17:S149-94. 2005..Awareness of these disorders, allied with recent advances in genetic, biochemical and neuroimaging techniques, may lead to early diagnosis, successful treatment and better prognosis... - 11C-PIB binding is increased in patients with cerebral amyloid angiopathy-related hemorrhageJ V Ly
National Stroke Research Institute, Level 1, Neurosciences Building, Austin Health, University of Melbourne, 300 Waterdale Rd, Heidelberg Heights, Victoria 3081, Australia
Neurology 74:487-93. 2010..We hypothesized that patients with a clinical diagnosis of CAA-related hemorrhage (CAAH) have increased (11)C-PIB uptake and that the pattern differs from Alzheimer disease (AD)...